Chamber and committees

I refer the member to the answer to question S6W-02045 on 25 August 2021. All answers to written Parliamentary Questions are available on the Parliament's website, the search facility for which can be found at https://www.parliament.scot/chamber-and-committees/written-questions-and-answers

The following table shows the number of samples collected within the cervical screening programme from 1 January 2019 to 26 August 2021. As part of the response to the COVID-19 pandemic, the cervical screening programme was paused between 30 March 2020 and 29 June 2020. The table below shows that a small number of samples were collected during this time; this is because colposcopy and gynaecology continued taking samples for clinical management, and some GP practices continued screening for those on non-routine recall.

Screening resumed on 29 June 2020 in a phased, careful and prioritised way, as part of the remobilisation of the NHS in Scotland. Anyone who was invited for cervical screening before the pause in March and had yet to make an appointment or had it cancelled was able to make an appointment from 29 June 2020. Non-routine cervical screening appointments resumed in mid-July and routine screening appointments from September 2020.

It is important to note that the data below is management information and has not been subject to the necessary quality checks carried out for an official publication.

The following table shows the number of people who attended an abdominal aortic aneurysm screening appointment between January 2019 and July 2021. The programme was paused between 30 March 2020 and 6 July 2020 and when screening resumed it prioritised higher-risk screening participants.

It is important to note that the data below is management information and has not been subject to the necessary quality checks carried out for an official publication.

I refer the member to the answer to question S6W-02419 on 21 September 2021. All answers to written Parliamentary Questions are available on the Parliament's website, the search facility for which can be found at https://www.parliament.scot/chamber-and-committees/written-questions-and-answers

Waiting time statistics for patients requiring treatment related to MS is not held centrally by the Scottish Government or Public Health Scotland (PHS). Patients’ specific condition or diagnosis is not collected by the PHS Waiting Times Team.

In regards to improving early diagnosis and understanding symptoms, the Scottish Government has provided a total of £650,000 funding to the Future MS project led by the University of Edinburgh. Future MS involves the collection of clinical data and biological samples from recently diagnosed, treatment naïve, relapsing-onset multiple sclerosis patients in order to develop a more personalised approach to clinical management. The project has recruited more than 400 MS patients from across all the territorial NHS Boards in Scotland.

We will invest £4.5 million over 5 years to implement the 17 commitments of the Neurological Care and Support in Scotland: A Framework for Action 2020 – 2025 . The aims include improving the provision of co-ordinated health and social care and support, developing sustainable workforce models and ensuring high standards of person-centred care for those with neurological conditions, such as MS. Over £300,000 has been committed so far to projects which improve the health and wellbeing of people with MS in Scotland, via the Framework.

The Scottish Government maintains positive relationships with third sector partners such as the MS Society, the MS Trust and Revive MS Support, supporting them to complement services provided by NHS Boards and improve understanding of the early symptoms of MS.

The Scottish Government does not hold national data for infectious diseases screening, antenatal haemoglobinopathies screening, or foetal anomaly ultrasound examinations within the pregnancy screening programme. These can be requested directly from individual NHS boards.

The following table shows the number of trisomy screens taken between January 2019 and June 2021.

It is important to note that the data provided below is management information and has not been subject to the necessary quality checks carried out for an official publication.

I refer the member to the answer to question S6W-02419 on 21 September 2021. All answers to written Parliamentary Questions are available on the Parliament's website, the search facility for which can be found at https://www.parliament.scot/chamber-and-committees/written-questions-and-answers

The Scottish Government does not hold information on the newborn hearing test and newborn infant physical examination. These would need to be requested from health boards directly.

The following table shows the number of babies screened using the bloodspot test in the newborn screening programme between January 2019 and July 2021.

It is important to note that the data provided below is management information and has not been subject to the necessary quality checks carried out for an official publication.

As part of the NHS Scotland response to coronavirus (COVID-19), an Innovation Workstream has been created to manage the evaluation of antibody and swab (PCR) tests. This workstream is led by NHS NSS and clinical scientists from NHS Health Boards, and is designed to take advantage of rapid innovations within testing, while at the same time avoiding duplication of effort between Health Boards.

As part of this workstream, antibody tests being used within Scotland are validated by NHS Scotland. The evaluation reports for the antibody assays which have currently been validated and are in use are publicly available, and can be found on NHS Scotland’s Health Innovation Assessment Portal . These evaluation reports show the high sensitivity and specificity of antibody tests approved for use within Scotland.

Scotland is also part of the UK National Testing Programme, participating in UK-wide antibody studies such as the Post Positive PCR Antibody Testing Initiative, where antibody tests have been validated by the UK Government. These validation reports are publicly available, and can be found on the UK Government website .

Advice from clinicians is to continue to use PCR testing for international travel, which is more accurate than other forms of testing. In addition, positive results should be genomically sequenced, which is harder to do using other types of test. We will, however, consider the use of lateral flow testing as technology improves and more data is available. Regardless of any testing regime, individuals should be following the protocols set out to minimise transmission.